The growing body of evidence implicating tumor necrosis factor-a (TNFa) in the pathophysiology of psychiatric disorders led us to measure levels of that protein in the cortex of subjects with major depressive disorders (MDD). Having reported an increase (458%) in the levels of the transmembrane (tmTNFa), but not the soluble (sTNFa), form of the protein in Brodmann's area (BA) 46, but not 24, in people with the disorder, we decided to examine additional components of TNFa-related pathways in the same regions in people with MDD and extend our studies to the same cortical regions of people with schizophrenia (Sz) and bipolar disorders (BD). Using postmortem tissue, western blots and quantitative PCR, we have now shown there is a significant increase (305%) in tmTNFa in Brodmann's area 24, but not 46, from subjects with BD, and that levels of the protein were not altered in Sz. Levels of sTNFa were not altered in BD or Sz. In addition, we have shown that levels of TNF receptor 1 (TNFR1) mRNA are increased in BA 24 (53%) and BA 46 (82%) in people with Sz, whereas levels of TNFR2 mRNA was decreased in BA 46 in people with mood disorders (MDD ¼ À51%; BD ¼ À67%). Levels of proteins frequently used as surrogate markers of neuronal, astrocytic and microglia numbers, as well as levels of the pro-inflammatory marker (interleukin 1b), were not changed in the cortex of people with mood disorders. Our data suggest there are differential changes in TNFa-related markers in the cortex of people with MDD, BD and Sz that may not be related to classical inflammation and may cause changes in different TNFa-related signaling pathways.
INTRODUCTION
A growing body of evidence implicates inflammatory-related pathways in the pathophysiology of psychiatric disorders. 1 Importantly, most of these data come from the study of cytokines in blood with one of the most consistent findings being that levels of tumor necrosis factor-a (TNFa) are increased in people with psychiatric disorders. 2--21 Despite this evidence suggesting a role for TNFa in the pathophysiology of psychiatric disorders no studies on that protein had been performed in the central nervous system (CNS) of individuals with these disorders. This led us to measure levels of TNFa in the cortex of subjects with major depressive disorders (MDD). 22 We commenced our studies in MDD because this was the disorder where increased peripheral TNFa was most consistently reported. We measured levels of TNFa in the dorsolateral prefrontal cortex (Brodmann's area 46 (BA 46)) and anterior cingulate (BA 24). We chose to make our measurements in BA 46 because it is important in maintaining cognitive function 23 and BA 24 because of its involvement in the control of mood; 24 behaviors that have both been shown to be aberrant in MDD. 25 Our data showed there was a 458% increase in the levels of the transmembrane (tmTNFa), but not soluble (sTNFa), form of TNFa in BA 46, but not BA 24, from subjects with MDD. 22 Much is known about the processing of TNFa, allowing interpretation of our data in MDD. Human TNFa is encoded by a single gene on chromosome 6 (6p21.3) and TNFa is initially synthesized as a monomeric type-2 transmembrane protein that forms a homotrimer, known as tmTNFa. 26 tmTNFa has a long leader sequence that forms an intracellular domain of 30 amino acids, a transmembrane domain of 26 amino acids and a 20 amino acid extracellular domain. 27 tmTNFa can undergo cleavage by a number of metalloproteases, the predominant being TNFa-converting enzyme (ADAM metallopeptidase domain 17: ADAM17), that gives rise to sTNFa, 26 which exists in the extracellular milieu and can have paracrine effects. The complexity of tmTNFa signaling is highlighted by the fact that ADAM17 and other metalloproteases can cleave both TNF receptor 1 (TNFR1) and TNFR2 to give soluble forms of both receptors. 28 This means that TNFa signaling can occur by three mechanism that are: (i) sTNF activating TNFR1 or TNFR2 giving forward signaling, (ii) sTNFR1 or sTNFR2 activating tmTNF giving reverse signaling or (iii) tmTNF interacting with TNFR1 or TNFR2 to activate both forward and reverse signaling. 1 The physiological potencies of these interactions are governed by the fact that sTNF binds with high affinity to TNFR1 whereas tmTNFa binds with higher affinity to TNFR2. 28 These data suggest that sTNF predominantly signals via TNFR1, whereas tmTNF and sTNFR2 interactions would be more potent in activating reverse signaling. Finally, interactions between tmTNFa and TNFR2 are likely to be the most potent combination in activating forward and reverse signaling.
Our data are significant in that they suggest that tmTNFa is altered in the cortex of subjects with MDD, rather than sTNFa, which is the form of TNFa measured in blood. Given the role of tmTNFa, it would seem reasonable to postulate that increased levels of this protein would be affecting levels of tmTNFa signaling in BA 46, but not BA 24, in people with MDD. The notion that changes in tmTNFa are involved in the pathophysiology of MDD is given credence by the fact that tmTNFa is a pharmacological site 29 and drugs that target tmTNF have antidepressant properties. 30, 31 Thus, following the concept that a good understanding of the underlying pathophysiology of a psychiatric disease will aid in developing better therapeutic agents to treat psychiatric disorders, 32 we decided to determine whether other critical components of the TNF-related pathways were altered in BA 46 and BA 24 in people with MDD and whether such changes extended to the same CNS regions in bipolar disorder (BD) and schizophrenia (Sz). Moreover, the end point of chronic inflammatory processes in the CNS would be an increase in cell death 33 following an increase in microglia/macrophage activation. 34 Thus, we decided to measure the levels of well-established protein markers that have been shown to vary with changes in pre- 35 and postsynaptic 36 density (synaptophysin and PSD95, respectively), astrocyte number (GFAP) 37 and microglia/macrophage number (CD11b) 38 in the cortex of people with mood disorders to begin to determine whether changes in TNFa-related pathways were reflecting a pro-inflammatory activity. Following on this theme, we also measured levels of interleukin 1b (IL1B) in the cortex of subjects with mood disorders as this protein and TNFa are increased in unison as part of increased classical pro-inflammatory activity. 39 
MATERIALS AND METHODS

Tissue collection
The permission to collect human CNS tissue was obtained from the Ethics Committee of the Victorian Institute of Forensic Medicine, and the tissue was collected after obtaining permission from the closest surviving next of kin. Permission to complete specific studies was obtained from the Mental Health Research and Ethics Committee of Melbourne Health. All human tissue was sourced through the Victorian Brain Bank Network, Mental Health Research Institute, Parkville, Australia.
CNS left hemispheres were collected from people who had been seen alive up to 5 h before being found dead and where cadavers had been refrigerated within 5 h of discovery; refrigeration of cadavers would act to slow CNS autolysis, 40 and thus reduce the impact of PMI. For each case, postmortem interval (PMI) was calculated as the time between witnessed death and autopsy or the midpoint between the subject being found and being last seen alive and autopsy. To further optimize CNS preservation, each hemisphere was processed in a standardized manner to ensure tissue was frozen to À70 1C within 30 min of autopsy. 41 To obtain a measure of autolytic damage, CNS pH was measured as described previously 42 as this is now recognized as giving a better indication of the quality of tissue preservation, which is often not related simply to PMI. 43 RNA integrity numbers (RINs) were obtained to provide an assessment of mRNA integrity. 43 Following tissue collection and processing an extensive case history review was completed, including a pharmacological audit. On completion of the case history review a consensus DSM-IV-based diagnosis was agreed by two senior psychiatrists and the psychologist completing the case history review. 44, 45 The duration of illness (DOI) in years was also calculated. In addition, the final recorded antipsychotic, anticholinergic, antidepressant and benzodiazepine drug doses were converted to standardized units according to principles outlined previously. 46 Diagnostic cohorts Studies were completed using tissue from 10 people with MDD, 10 people with BD, 19 people with Sz and 30 age-and sex-matched control subjects (summary: Table 1 ; full details: Supplementary Table 1 ). Owing to issues relating to tissue availability studies were completed using three control groups; the one for people with Sz consisting of 20 subjects (control Group A: Table 1 and Supplementary Table 1) . For the initial studies of TNF-related measures, results were compared with a subgroup of 10 individuals from Group A (control Group B). Due to shortage of tissue in some controls, the studies on cellular markers were completed on a new cohort of 10 control subjects control Group C matched by age/sex to both control Group B (Table 1 ) and the psychiatric cohorts.
Western blot analyses
Levels of sTNFa and tmTNFa were measured by western blot analyses as described previously, 22 and the levels of other proteins were measured using methodology based on the approaches we have used extensively for other proteins, 47--49 but optimized for the measurement of each protein of interest (Supplementary Table 2 ). Importantly, the person completing the analyses was blind to diagnoses but the coding of the samples ensured that a case and their matched control were on the same gel. Two images Table 1 . Summary of demographic, brain collection and preservation data (mean ± s.e.m.) relating to donors of tissue used in the study of tumor necrosis factor 1-a-related pathways in the pathophysiology of psychiatric disorders TNF-related pathways in psychiatry B Dean et al were captured (light mode for the molecular weight standards and chemiluminescent for the immunogenic bands) and merged to allow the estimation of the molecular weight of each antigenic band. The densities of the immunogenic bands were measured on the chemiluminescent image and expressed as a ratio of the corresponding immunogenic band in the internal control to accommodate gel-to-gel variation. As we have shown previously, 48, 49 this approach also allows comparisons of levels of proteins within and across CNS regions.
RNA purification and first-strand cDNA synthesis Total RNA was isolated from 100 mg frozen cortical samples with 1.0 ml TRIzol s reagent (Invitrogen, Mulgrave, Victoria, Australia) for human tissue and QIAGEN (Chadstone, Victoria, Australia). Following TRIzol extraction, the RNA was treated with 0.1 U ml À1 DNAse in 1 Â DNAse buffer (Invitrogen) to remove genomic DNA contamination, extracted using phenol (pH 4.2): chloroform extraction and ethanol precipitated. cDNA was synthesized as described previously. 50 Real-time PCR assay cDNA was used as a template for real-time PCR performed with SYBR green detection using a Bio-Rad iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories, Gladesville, New South Wales, Australia). Reactions were performed in triplicate as previously described. 49 Relative quantities were calculated from C t values using the amplification efficiency for each gene. Efficiencies of each primer set were established across four 10-fold serial dilutions of amplified target sequence, spanning the C t range of the target gene in the cDNA. Levels of mRNA for each gene of interest were expressed as the geometric mean of three reference genes. 51 Genevestigator (www.genevestigator.com) was used to initially select five stably expressed reference genes with similar expression levels to the target genes. mRNA levels of the five most stably expressed genes identified were measured in five subjects with BPD, five subjects with MDD, five subjects with Sz and five controls using qPCR to assess the stability of reference gene expression within and between diagnosis. Expression level stability was then analyzed using geNorm (Biogazelle, Zwijnaarde, Belgium). The three most stably expressed genes, SKP1A (M ¼ 0.054), NOL9 (M ¼ 0.54) and TFB1M (M ¼ 0.057), were selected as reference genes for further analysis, where the gene stability measures (M) o1.5 were deemed suitable for use as reference genes. 52 Primers were designed using Beacon design software (Premier Biosoft International, Palo Alto, CA, USA; Supplementary Table 3 ) and amplicons were confirmed by sequencing before experimentation.
Statistical analyses
Donor demographic, drug and CNS collection data were compared between cohorts using either one-way analysis of variance followed by a post hoc Bonferroni test comparing data across cohorts (multiple cohorts) or Student t-tests (two cohorts). The sex ratios in each cohort were compared using a Fisher's exact test.
All experimental data were analyzed using the D'Agostino and Pearson omnibus normality test to determine the distribution of data as this is the best way of determining data distribution in small cohorts. 53 If data were normally distributed, outlying data were first identified using Grubb's test 54 (maximal allowable 1 per measurement) and any outlying data point was removed from further analyses. For our protein data, the use of the same IC across regions made results between regions comparable. Thus, normally distributed data were analyzed with two-way analysis of variance with CNS region and diagnoses as variants followed by a post hoc Dunnet's comparison to control data to identify any source of variance. As our qPCR data could not be compared across regions a one-way analysis of variance followed by a post hoc Dunnet's comparison to control data was used to identify sources of variance within each region. Where the distribution of data in different diagnostic cohorts showed mixed variance data were analyzed using the General Linear Model with Bonferroni post hoc testing as this is a robust approach to analyzing such data. 55 Where data were shown to be uniformly non-parametric, the appropriate non-parametric analyses was used.
Relationships between demographic, brain collection and pharmacological data from each donor and experimental data were interrogated using linear regression. Where strong significant relationships 56 were revealed comparison of experimental data across diagnoses was reassessed using an analysis of covariance with the identified variables as cofactors.
RESULTS AND DISCUSSION
The complete analyses of variation in protein levels between cortical regions is given in Supplementary Data 1.
Analyses of patient demographics and tissue collection parameters There were no significant variations in mean age, sex ratio, PMI, CNS pH, or RIN between subjects with Sz and their controls (Table 1: control Group A). For studies on TNF-related measures involving control Cohort B, there was no significant variation in mean age, gender ratio PMI or RIN across the diagnostic cohorts but there was significant variation in CNS pH (Table 1) . This increased variation in CNS pH was due to higher values for MDD compared with controls (Po0.05). For studies on cellular markers and IL-1b, using control Cohort C, there was no significant variation in mean age, sex ratio, PMI or RIN between diagnostic cohorts but there was significant variation in CNS pH (Table 1) . This increased variation in CNS pH was again due to higher values for MDD compared with controls (Po0.05).
TNFa-related measures Levels of tmTNFa were increased (158%; Po0.05) in BA 24, but not BA 46, in subjects with BD and were not different in either cortical regions in people with Sz ( Figure 1 ). By contrast, levels of sTNFa did not vary significantly with diagnosis (P ¼ 0.38: Table 2 ) in cortex from subjects with mood disorders. There was a trend to a significant variation in data with diagnosis (P ¼ 0.06: Figure 2a (Table 2) . By contrast, level of TNFR1 mRNA was significantly increased in both BA 24 (53%; P ¼ 0.03) and BA 46 (82%, Po0.001) in people with Sz (Figure 2b ). There was significant variation in levels of TNFR2 mRNA with diagnoses in BA 46, but not BA 24, in people with mood disorders due to decreased levels of mRNA in the cortex of people with BD (79%; Po0.001) and MDD (50%, Po0.001) (Figure 3 ).
Measures of cellular markers and inflammatory pathways
Despite optimizing western blot conditions to detect IL1B, we were unable to detect that protein in any cortical sample. By contrast, we were able to visualize IL1B in a western blot using cortical tissue from a subjects with meningitis. We were able to detect the IL1B precursor protein, pro-IL1B, 57 in all cases. Levels of synaptophysin, PSD95, GFAP43, GFAP41, CD11b or pro-IL1B did not vary with diagnoses in cortex in people with mood disorders (Table 2) .
Potential confounding factors
In the overall analyses (independent of diagnoses), there were no strong correlations between any experimental factor and any confounding factors. There were few strong significant correlations between experimental measurements and potential confounding factors within diagnosis (Supplementary Table 4 ). There were strong significant correlations between levels of tmTNFa in BA 24 and PMI in control subjects (r 2 ¼ 0.56; Po0.01), TNF mRNA and age (r 2 ¼ 0.50; Po0.05) in BA 46 from MDD, TNFR1 mRNA and A re-analysis of the TNF and TNFR2 mRNA in mood disorders with PMI and brain pH as covariates showed significant variance remained with diagnoses (F ¼ 9.0, d.f. ¼ 1,1,36, P ¼ 0.005 and F ¼ 8.2, d.f. ¼ 1,2,53, P ¼ 0.001). In comparing TNF mRNA and TNFR1 mRNA with age as a covariant, the effect of diagnoses remained nonsignificant for both measures (F ¼ 9.7, 1,2,53, P ¼ 0.19 and F ¼ 1.2, 1,2,53, P ¼ 0.33). Similarly, in the mood disorders, analyses of synaptophysin and GFAP41 with brain pH and PMI, respectively, as a covariant showed the effect of diagnoses remained non-significant (F ¼ 0.81, 1,2,53, P ¼ 0.45, F ¼ 0.23, 1,2,53, P ¼ 0.79). Finally, comparing levels of synaptophysin in mood disorders with DOI as a covariant showed there was still no significant variance with diagnoses (F ¼ 0.29, d.f. ¼ 1,1,34, P ¼ 0.58). These data suggest that the impact of the potential confounds identified in this study are not of sufficient strength to alter the interpretation of the comparison of experimental data across diagnosis.
Added to our earlier finding, 22 our current data suggest there are changes in TNFa-related pathways in mood disorders and Sz. We found increased TNFR1 mRNA in the cortex of Sz, a result that was not expected and does not appear to have been reported elsewhere. As the only clearly significant change in TNFa-related markers in the cortex of people with Sz our data suggest further studies on TNFR1 signaling in Sz would be worthwhile. Importantly, TNFR1 recruits a number of intracellular adaptor proteins to facilitate signaling, and activation of TNFR1 signaling can have a number of disparate outcomes such as changes in gene expression and/or apoptosis. 58 One of the proteins recruited by TNFR1, TNF receptor-associated factor 2, has been suggested to be important in the actions of DISC1, 59 which is a gene implicated in changing the risk for developing Sz. 60 These data show that TNF signaling through TNFR1 can affect multiple pathways, some of which seem to be particularly relevant to Sz, which suggests a better understanding of the changes in TNFR1-related pathways in the cortex of subjects with the disorder will add to our knowledge of its pathophysiology.
Our data suggest there are complex changes in TNFa-related pathways in the cortex of people with mood disorders. However, in addition to failing to identify changes in sTNFa in the cortex of people with mood disorders, IL1B levels were too low to detect and levels of pro-IL1B did not change with diagnoses. Importantly, sTNF and IL1B have been shown to increase with increases in pro-inflammatory activity. 39, 61 Similarly, our data showing that CD11b (surrogate microglia/macrophages markers) was not increased in the cortex of people with mood disorders, which is also not consistent with what would be expected in tissue in which there are ongoing pro-inflammatory processes. 61, 62 Hence, our data argue that changes in TNFa-related pathways in mood disorders have not resulted from increased proinflammatory activity. This argument is further supported by the absence of change in markers of neuronal integrity (synaptophysin and PSD95: surrogate markers of neuronal connections), which would be expected to be decreased after chronic inflammation. 33 As with all early studies involving a low number of cases, caution needs to be applied to overinterpretation. However, the changes we report are large (Mood disorders: increase in tmTNFa BA 24 BD ¼ 158%, decrease in TNFR2 mRNA BA 46 ¼ À67% BD and À51% MDD) and it is therefore unlikely these are simply a function of low diagnostic cohorts especially as a retrospective power analyses showed that the adequate cohort sizes, given the differences in our data with diagnoses, would be 10 for tmTNFa and three for both measures of TNFR2.
In interpreting our data on TNFa-related pathways in the cortex of people with psychiatric disorders, it is important that current data suggest that TNFa signaling would predominantly involve sTNFa-TNFR1 and tmTNFa-TNFR2 interactions. 26 Our current and previous data 22 would argue that alterations in tmTNFa-TNFR2 pathways are present in mood disorders whereas it is sTNFa-TNFR1 signaling pathways that are altered in Sz. This delineation is important because (i) the TNF gene is predominantly expressed by astrocytes 63 and microglia 64 and hence tmTNF is on these cells, (ii) TNFR2 is predominantly expressed by microglia and neurons, 26 and (iii) TNFR1 is thought to ubiquitously expressed by all cells. 26, 65 Therefore, the changes in TNF-related pathways in mood disorders should have more restricted outcomes compared with those in Sz. In addition, paracrine signaling through sTNFa appears to be generally linked to pathological process whereas tmTNF signaling appears to be linked more to 'therapeutic' responses. 58 Hence, our data argue that changes in TNFa-related pathways in the cortex of people with mood disorders may be a response that is designed to oppose the pathophysiological process associated with MDD and BD, whereas the changes in Sz may be directly contributing to the pathophysiology of that disorder.
We are not aware of any previous studies that have focussed on TNFa-related pathways in the cortex of subjects with psychiatric disorders, particularly in people with mood disorders. Our data from people with mood disorders showing increased levels of tmTNF in BA 24 in people with BD and BA 46 in people with MDD open up the possibility of increased reverse signaling 1, 58 by that protein in these cortical regions. However, the changes in TNFR2 mRNA in BA 46 from subjects with MDD and BD could be indicating a change in bidirectional signaling 1 in that region. This could certainly be the case in BA 46 in people with MDD where levels of tmTNF and TNFR2 mRNA are changed. Given that the dorsolateral prefrontal cortex (BA 46) is known to be critical in maintaining cognitive processes, 23 it would not be unreasonable to posit that changes in TNFa-related pathways could be involved in the changes in cognition that are known to occur in MDD 25 and BD. 66 Similarly, the anterior cingulate (BA 24) is important in controlling mood 24 and therefore changes in TNFa-related pathways could be involved in changes in mood that particularly affects people with BD. 67 Such hypotheses gain support from the 68 Particularly important to our data is the finding that drugs that target tmTNF have mild antidepressant activity. 30, 31 Therefore, it would seem likely that a better understanding of changes in tmTNFa and TNFa-related pathways in the CNS from subjects with mood disorders would cast light on why drugs that target tmTNF have antidepressant activity. More importantly, a better understanding of how TNFa-related pathways are affected in the CNS of people with mood disorders could suggest better targets in the pathway for more effective intervention that should lead to drugs of greater therapeutic efficacy and, given the problem of treatment resistant depression, 69 therapeutic reach.
